Assessment of peripheral blood CD4+ adenosine triphosphate activity in patients with rheumatoid arthritis

References

• Kowalski RJ, Post DR, Mannon RB, Sebastian A, Wright HI, Sigle G, et al. Assessing relative risks of infection and rejection: a meta-analysis using an immune function assay. Transplantation. 2006;82:663–8.
   PubMed Web of Science ®Google Scholar
• Sanchez-Velasco P, Rodrigo E, Valero R, Ruiz JC, Fernandez-Fresnedo G, Lopez-Hoyos M, et al. Intracellular ATP concen-trations of CD4 cells in kidney transplant patients with and without infection. Clin Transplant. 2008;22: 55–60.
   Google Scholar
• Gupta S, Mitchell JD, Markham DW, Mammen PP, Patel PC, Kaiser PA, et al. Utility of the Cylex assay in cardiac transplant recipients. J Heart Lung Transplant. 2008;27:817–22.
   PubMed Web of Science ®Google Scholar
• Bhorade SM, Janata K, Vigneswaran WT, Alex CG, Garrity ER. Cylex ImmuKnow assay levels are lower in lung transplant recip-ients with infection. J Heart Lung Transplant. 2008;27:990–4.
   Google Scholar
• Kowalski R, Post D, Schneider MC, Britz J, Thomas J, Deierhoi M, et al. Immune cell function testing: an adjunct to therapeutic drug monitoring in transplant patient management. Clin Trans-plant. 2003;17:77–88.
   PubMed Web of Science ®Google Scholar
• Serban G, Whittaker V, Fan J, Liu Z, Manga K, Khan M, et al. Significance of immune cell function monitoring in renal trans-plantation after thymoglobulin induction therapy. Hum Immunol. 2009;70:882–90.
   PubMed Web of Science ®Google Scholar
• Pareja JG, Garland R, Koziel H. Use of adjunctive corticosteroids in severe adult non-HIV Pneumocystis carinii pneumonia. Chest. 1998;113:1215–24.
   Google Scholar
• Kovacs JA, Hiemenz JW, Macher AM, Stover D, Murray HW, Shelhamer J. Pneumocystis carinii pneumonia: a comparison between patients with the acquired immunodeficiency syndrome and patients with other immunodeficiencies. Ann Intern Med. 1984;100:663–71.
   PubMed Web of Science ®Google Scholar
• Smolen JS, Landewe R, Breedveld FC, Dougados M, Emery P, Gaujoux-Viala C, et al. EULAR recommendations for the man-agement of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis. 2010;69:964–75.
   Google Scholar
• Balandraud N, Roudier J, Roudier C. What are the links between Epstein-Barr virus, lymphoma, and tumor necrosis factor antagonism in rheumatoid arthritis? Semin Arthritis Rheum. 2005;34:31–3.
   Google Scholar
• Dias C, Isenberg DA. Susceptibility of patients with rheumatic diseases to B-cell non-Hodgkin lymphoma. Nat Rev Rheumatol. 2011;7:360–8.
   PubMed Web of Science ®Google Scholar
• Harrington LE, Hatton RD, Mangan PR, Turner H, Murphy TL, Murphy KM, et al. Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol. 2005;6:1123–32.
   PubMed Web of Science ®Google Scholar
• Park H, Li Z, Yang XO, Chang SH, Nurieva R, Wang Y, et al. A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat Immunol. 2005;6:1133–41.
   PubMed Web of Science ®Google Scholar
• Spriggs MK. Interleukin-17 and its receptor. J Clin Immunol. 1997;17:366–9.
   PubMed Web of Science ®Google Scholar
• Acosta-Rodriguez EV, Napoletani G, Lanzavecchia A, Sallusto F. Interleukins 1/3 and 6 but not transforming growth factor-/3 are essential for the differentiation of interleukin 17-producing human T helper cells. Nat Immunol. 2007;8: 942–9.
   Google Scholar
• Chen Z, Tato CM, Muul L, Laurence A, O'Shea JJ. Distinct regulation of interleukin-17 in human T helper lymphocytes. Arthritis Rheum. 2007;56: 2936–46.
   Google Scholar
• Wilson NJ, Boniface K, Chan JR, McKenzie B, Blumenschein WM, Mattson JD, et al. Development, cytokine profile and function of human interleukin 17-producing helper T cells. Nat Immunol. 2007;8:950–7.
   PubMed Web of Science ®Google Scholar
• van Beelen AJ, Zelinkova Z, Taanman-Kueter EW, Muller FJ, Hommes DW, Zaat SAJ, et al. Stimulation of the intracellular bacterial sensor NOD2 programs dendritic cells to promote interleukin-17 production in human memory T cells. Immunity. 2007;27: 1–10.
   Google Scholar
• Ouyang W, Kolls JK, Zheng Y. The biological functions of T helper 17 cell effector cytokines in inflammation. Immunity. 2008;28: 454–67.
   Google Scholar
• Bernatsky S, Hudson M, Suissa S. Anti-rheumatic drug use and risk of serious infections in rheumatoid arthritis. Rheumatology. 2007;46:1157–60.
   Google Scholar
• Lacaille D, Guh DP, Abrahamowicz M, Anis AH, Esdaile JM. Use of nonbiologic disease-modifying antirheumatic drugs and risk of infection in patients with rheumatoid arthritis. Arthritis Rheum. 2008;59:1074–81.
   Google Scholar
• Franklin J, Lunt M, Bunn D, Symmons D, Silman A. Risk and predictors of infection leading to hospitalisation in a large pri-mary-care-derived cohort of patients with inflammatory polyar-thritis. Ann Rheum Dis. 2007;66:308–12.
   Google Scholar
• Doran MF, Crowson CS, Pond GR, O'Fallon WM, Gabriel SE. Predictors of infection in rheumatoid arthritis. Arthritis Rheum. 2002;46:2294–300.
   PubMed Web of Science ®Google Scholar
• Smitten AL, Choi HK, Hochberg MC, Suissa S, Simon TA, Testa MA, et al. The risk of hospitalized infection in patients with rheumatoid arthritis. J Rheumatol. 2008;35:387–93.
   PubMed Web of Science ®Google Scholar
• Wolfe F, Caplan L, Michaud K. Treatment for rheumatoid arthritis and the risk of hospitalization for pneumonia: associa-tions with prednisone, disease-modifying antirheumatic drugs, and anti-tumor necrosis factor therapy. Arthritis Rheum. 2006;54:628–34.
   Google Scholar
• Edwards CJ, Cooper C, Fisher D, Field M, van Staa TP, Arden NK. The importance of the disease process and disease-modifying antirheumatic drug treatment in the development of septic arthritis in patients with rheumatoid arthritis. Arthritis Rheum. 2007;57: 1151–7.
   PubMed Web of Science ®Google Scholar
• Dixon WG, Kezouh A, Bernatsky S, Suissa S. The influence of systemic glucocorticoid therapy upon the risk of non-serious infection in older patients with rheumatoid arthritis: a nested case—control study. Ann Rheum Dis. 2011;70:956–60.
   PubMed Web of Science ®Google Scholar
• Cronstein BN, Eberle MA, Gruber HE, Levin RI. Methotrexate inhibits neutrophil function by stimulating adenosine release from connective tissue cells. Proc Natl Acad Sci USA. 1991;88:2441–5.
   PubMed Web of Science ®Google Scholar